Nabil Ismaili, Director of Medical Oncology and Radiotherapy Department at Mohammed VI University of Sciences and Health , shared a post on LinkedIn:
“Thrilled to share our latest review article published in Frontiers in Immunology!
Title: Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host
In this work, we critically examine the shift from a purely tumor‑centric view of predictive biomarkers (PD‑L1, MSI, TMB, EBV) toward a more integrative, dynamic, host–tumor framework for gastric cancer immunotherapy.
Key messages:
- Autoantibodies (ANA/ENA) and systemic inflammation markers (NLR, PLR) are emerging as promising prognostic tools.
- The gut microbiome, microbial metabolites (succinate, butyrate), and even cancer‑induced nerve injury from murine models offer novel translational insights.
- We propose a three‑step conceptual framework (Figure 1) that integrates host‑centric and tumor‑centric markers to personalize patient selection.
A very special thank you to Mr. Lachmi Nadel – his courage and generosity in supporting cancer research, even while facing his own battle, made this publication possible. This work is dedicated to his strength and to the hope for better outcomes for all patients.
Read the full article here (Open Access):
What do you think is the most urgent next step: validating autoantibodies, exploring the gut microbiome, or integrating machine learning models?”
Other articles featuring Nabil Ismaili on OncoDaily.